PDL BioPharma's Third-Quarter Revenue Grew 14%

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

PDL BioPharma  (NASDAQ: PDLI  )  forecasts revenue for the quarter ending September 30, 2013, its third, to land at approximately $97 million. This guidance represents a 14% improvement over the $85 million it generated in the same period last year. This comes after it reported revenue growth in the second quarter of this year at approximately 14% year over year.

PDL expects revenue growth to be primarily driven by royalties for the sales of Avastin, Herceptin, Lucentis, Xolair, Perjeta, and Kadcyla, which are all drugs sold by Roche, a Swiss health-care company that acquired Genentech in March 2009. Avastin, Herceptin, and Lucentis accounted for approximately 87% of PDL's total revenue in the second quarter of this year.

It should be noted the guidance provided by PDL is net of the estimated amount that is paid to Novartis AG per a February 2011 settlement regarding the sales of Lucentis. The settlement stipulates that PDL pays Novartis dependent on the total sales of Lucentis, which is less than the royalties PDL receives from those sales.

PDL BioPharma is a biopharmaceutical company that through patented processes creates antibodies, which allow the human body to fight and defend against invasion from foreign substances, primarily pathogens and toxins.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2629380, ~/Articles/ArticleHandler.aspx, 11/29/2015 2:01:07 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Patrick Morris

After a few stints in banking and corporate finance, Patrick joined the Motley Fool as a writer covering the financial sector. He's scaled back his everyday writing a bit, but he's always happy to opine on the latest headline news surrounding Berkshire Hathaway, Warren Buffett and all things personal finance.

Today's Market

updated 1 day ago Sponsored by:
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 1.24 0.06%
NASD 5,127.53 11.38 0.22%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/27/2015 12:59 PM
PDLI $3.97 Down +0.00 +0.00%
PDL BioPharma CAPS Rating: ****